Literature DB >> 12661473

Inappropriate use of oral terbinafine in family practice.

Michael Wilcock1, John Hartley, David Gould.   

Abstract

OBJECTIVE: To review whether oral terbinafine, used for fungal nail infections, is prescribed appropriately by general practitioners.
METHOD: Cross-sectional survey of forty volunteer practices. Prescribing systems were searched to identify patients who had been prescribed a course of oral terbinafine during 1998. The clinical records of five such patients in each practice were examined for additional information regarding appropriate diagnostic tests.
RESULTS: Five hundred sixty-nine patients (0.25% of the population aged 12 and over) were reported to have received a course of oral terbinafine. Sixty-four percent had been treated empirically without any recorded diagnostic test.
CONCLUSION: Treatment of onychomycosis with terbinafine is commonly undertaken without diagnostic confirmation. This empirical treatment does not comply with locally recommended good practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661473     DOI: 10.1023/a:1022426309340

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  8 in total

1.  A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis.

Authors:  V Havu; H Heikkilä; K Kuokkanen; M Nuutinen; T Rantanen; S Saari; S Stubb; R Suhonen; K Turjanmaa
Journal:  Br J Dermatol       Date:  2000-01       Impact factor: 9.302

Review 2.  Adverse drug reactions of the new oral antifungal agents--terbinafine, fluconazole, and itraconazole.

Authors:  B Amichai; M H Grunwald
Journal:  Int J Dermatol       Date:  1998-06       Impact factor: 2.736

3.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group.

Authors:  E G Evans; B Sigurgeirsson
Journal:  BMJ       Date:  1999-04-17

Review 4.  Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology).

Authors:  D W Denning; E G Evans; C C Kibbler; M D Richardson; M M Roberts; T R Rogers; D W Warnock; R E Warren
Journal:  BMJ       Date:  1995-11-11

5.  Onychomycosis is more than a cosmetic problem.

Authors:  R K Scher
Journal:  Br J Dermatol       Date:  1994-04       Impact factor: 9.302

6.  The impact of onychomycosis on quality of life.

Authors:  L R Whittam; R J Hay
Journal:  Clin Exp Dermatol       Date:  1997-03       Impact factor: 3.470

7.  Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey.

Authors:  D T Roberts
Journal:  Br J Dermatol       Date:  1992-02       Impact factor: 9.302

8.  A questionnaire study on the management of onychomycosis: a Canadian perspective.

Authors:  A K Gupta; N H Shear
Journal:  Int J Dermatol       Date:  1998-06       Impact factor: 2.736

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.